Inflammatory markers associated with coronary heart disease in persons with HIV infection

Current Infectious Disease Reports

Volumn 13, Issue 1, 2011, Pages 94-101

  Fichtenbaum, Carl J ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Coronary heart disease; D dimer; Endothelial dysfunction; High sensitivity C reactive protein; HIV; Inflammation; Interleukin 6; Surrogate markers

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ADIPONECTIN; ALPHA INTERFERON; AMYLOID A PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD27 ANTIGEN; CD40 LIGAND; D DIMER; DIDANOSINE; EMTRICITABINE; FIBRINOGEN; GELATINASE B; INDINAVIR; INTERLEUKIN 10; INTERLEUKIN 6; LEPTIN; LOPINAVIR PLUS RITONAVIR; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID RELATED PROTEIN 14; MYELOID RELATED PROTEIN 8; PADGEM PROTEIN; PROTHROMBIN; TENOFOVIR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC INFLAMMATION; CORONARY ARTERY ATHEROSCLEROSIS; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISCHEMIC HEART DISEASE; MORTALITY; SIDE EFFECT; VIRUS REPLICATION;

EID: 79551533155     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-010-0153-9     Document Type: Article

References (36)

1. •• Libby P, Ridker PM, Hansson GK: Inflammation in atherosclerosis. J Am Coll Cardiol 2009, 54: 2129-38. Excellent recent review of our current understanding of the role of innate and adaptive immunity in the development and progression of atherosclerosis.
2. GK Hansson 2005 Inflammation, atherosclerosis and coronary artery disease N Engl J Med 352 1685 1695 1:CAS:528:DC%2BD2MXjsFCltrc%3D 10.1056/NEJMra043430 15843671 (Pubitemid 40530235)
3. •• Ridker PM, Danielson E, Fonseca FAH, et al.: for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-207. Landmark randomized controlled trial demonstrating that rosuvastatin lowered vascular events by 44% in persons with an LDL < 130 and an hsCRP > 2.0 mg/L.
4. PW Serruys HM Garcia-Garcia P Buszman, et al. 2008 Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque Circulation 118 1172 1182 1:CAS:528:DC%2BD1cXhtVOiurjK 10.1161/CIRCULATIONAHA.108.771899 18765397
5. PM Ridker DA Morrow LM Rose, et al. 2005 Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial J Am Coll Cardiol 45 1644 1648 1:CAS:528:DC%2BD2MXktVOjtrs%3D 10.1016/j.jacc.2005.02.080 15893181 (Pubitemid 40704500)
6. DA Morrow Y Wang K Croce, et al. 2008 Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial Am Heart J 155 49 55 1:CAS:528:DC%2BD2sXhsVenurnO 10.1016/j.ahj.2007.08.018 18082488 (Pubitemid 350234770)
7. LpPLA(2) Studies Collaboration: Lipoprotein-associated phospholipase A(2) and the risk of coronary disease, stroke and vascular mortality: collaborative analysis of 32 prospective studies. Lancet 2010; 375: 1536-44.
8. GD Lowe A Rumley AD McMahon for the West of Scotland Coronary Prevention Group, et al. 2004 Interleukin 6, fibrin D-dimer and coagulation factors VII and XIIa in the prediction of coronary heart disease Arterioscler Thromb Vasc Biol 24 1529 1534 1:CAS:528:DC%2BD2cXmtValuro%3D 10.1161/01.ATV.0000135995.39488.6c 15205218 (Pubitemid 39050452)
9. P Welsh PH Whincup O Papacosta, et al. 2008 Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men Q J Med 101 785 791 1:STN:280:DC%2BD1cnivFajtQ%3D%3D
10. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group 2003 Combination antiretroviral therapy and the risk of myocardial infarction N Engl J Med 349 1993 2003 10.1056/NEJMoa030218 (Pubitemid 37448922)
11. M Mary-Krause L Cotte A Simon and the Clinical Epidemiology Group from the French Hospital Database, et al. 2003 Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men AIDS 17 2479 2486 10.1097/00002030-200311210-00010 14600519 (Pubitemid 38393320)
12. D Klein L Hurley C Queensbury S Sidney 2002 Do Protease Inhibitors Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 30 471 477 1:CAS:528:DC%2BD38XmvVWisb0%3D 12154337
13. Strategies for Management of Antiretroviral Therapy (SMART) Study Group WM El-Sadr JD Lundgren, et al. 2006 CD4+ count-guided interruption of antiretroviral treatment N Engl J Med 355 2283 2296 1:STN:280: DC%2BD28npvVSntw%3D%3D 10.1056/NEJMoa062360 17135583 (Pubitemid 44837777)
14. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group 2007 Class of Antiretroviral Drugs and the Risk of Myocardial Infarction N Engl J Med 356 1723 1735 10.1056/NEJMoa062744 (Pubitemid 46658704)
15. SG Worm C Sabin R Weber, et al. 2010 Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study J Infect Dis 201 318 330 1:CAS:528:DC%2BC3cXisFGqtLY%3D 10.1086/649897 20039804
16. SA Bozzette CF Ake HK Tam, et al. 2008 Long-term survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy J Acquir Immune Defic Syndr 47 338 341 1:CAS:528:DC%2BD1cXjt1enu7s%3D 10.1097/QAI.0b013e31815e7251 18176330 (Pubitemid 351619420)
17. •• D:A:D Study Group: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008, 371: 1417-26. Large, prospective, observational study of complications of HIV demonstrating higher risk of myocardial infarction with current use of abacavir or didanosine. Effect disappears 6 months after stopping drugs.
18. The SMART/INSIGHT and the D:A:D study groups 2008 Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV - infected patients AIDS 22 F17 F24 10.1097/QAD.0b013e32830fe35e
19. • Brothers CH, Hernandez JE, Cutrell AG, et al.: Risk of myocardial infarction and abacavir therapy: no increased across 52 GlaxoSmithKline sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009; 51: 20-8. Analysis of CHD events in randomized trials of abacavir versus placebo showed no clear effect, although the study was limited by only 63 endpoints in more than 14,000 subjects studied.
20. • Costagliola D, Lang S, Mary-Krauss M, Boccara F: Abacavir and cardiovascular risk: reviewing the evidence. Curr HIV/AIDS Rep 2010, 7: 127-33. Analysis of 10 recent trials demonstrated association or lack of association of abacavir with risk of myocardial infarction. Authors note that there were several confounding variables that could explain associations observed in some studies, including cigarette smoking, renal insufficiency, cocaine use, and/or injection drug abuse.
21. •• Kuller LH, Tracy R, Belloso W, et al.: for the INSIGHT SMART Group. Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection. PLoS Medicine 2008, 5; e203: 1496-1508. Nested case-control study of biomarkers showed a relationship between all-cause mortality and baseline IL-6, D-dimer, and hsCRP with the strongest association for the former two.
22. A Calmy A Gayet-Agerona F Montecucco, et al. 2009 HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial AIDS 23 929 939 1:CAS:528:DC%2BD1MXltlKqsrY%3D 10.1097/QAD.0b013e32832995fa 19425222
23. •• Tien PC, Choi AI, Zolopa AR, et al.: Inflammation and Mortality in HIV-Infected Adults: Analysis of the FRAM Study Cohort. J Acquir Immune Defic Syndr 2010; 55:316-322. Cross-sectional study with 5-year follow-up demonstrating that fibrinogen and hsCRP were associated with all-cause mortality in persons with HIV, most of whom were receiving antiretroviral therapy.
24. B Lau AR Sharrett LA Kingsley, et al. 2006 C-Reactive Protein Is a Marker for Human Immunodeficiency Virus Disease Progression Arch Intern Med 166 64 70 1:CAS:528:DC%2BD28Xps1Wkuw%3D%3D 10.1001/archinte.166.1.64 16401812 (Pubitemid 43063843)
25. JG Feldman P Goldwasser S Holman, et al. 2003 C-Reactive Protein Is an Independent Predictor of Mortality in Women With HIV-1 Infection J Acquire Immun Defic Syndr 32 210 214 1:CAS:528:DC%2BD3sXptFymtA%3D%3D
26. •• Kalayjian RC, Machekano RN, Rizk N, et al.: Pretreatment Levels of Soluble Cellular Receptors and Interleukin-6 Are Associated with HIV Disease Progression in Subjects Treated with Highly Active Antiretroviral Therapy. J Infect Dis 2010; 201:1796-1805. Higher pretreatment concentrations of sTNFR-1, sCD27, sCD40L, and plasma IL-6 were associated with a new AIDS-defining illness or death.
27. FJ Palella Jr SJ Gangeb L Benning, et al. 2010 Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study AIDS 24 1657 1665 1:CAS:528:DC%2BC3cXot1Wktbg%3D 10.1097/QAD.0b013e3283389dfa 20588104
28. Benson CRH, Zheng E, Smurzynski M, et al.: No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: Results from ACTG A5001 [Abstract 721]. 16th Conference on Retroviruses and Opportunistic Infections 8-11 February 2009; Montreal.
29. E Martinez M Larroussea D Podzamczer, et al. 2010 Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction AIDS 24 F1 F9 1:CAS:528:DC%2BC3cXpsVSnug%3D%3D 10.1097/QAD.0b013e32833562c5 20009917
30. Jong E, Meijers J, van Gorp E, et al.: Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir. AIDS Research and Therapy 2010, 7;9: 1-7.
31. Martin A, Amin J, Cooper DA, et al.; on behalf of the STEAL study group. Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. AIDS 2010, Sep 7. [Epub ahead of print]
32. PY Hsue PW Hunt E Sinclair, et al. 2006 Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses AIDS 20 2275 2283 10.1097/QAD.0b013e3280108704 17117013 (Pubitemid 44789529)
33. AC Ross MA O'Riordan N Storer, et al. 2010 Heightened inflammation is linked to carotid intima-media thickness and endothelial activation in HIV-infected children Atherosclerosis 211 492 498 1:CAS:528:DC%2BC3cXps1Clsrg%3D 10.1016/j.atherosclerosis.2010.04.008 20471650
34. M van Vonderen E Hassink M van Agtmael, et al. 2009 Increase in Carotid Artery Intima-Media Thickness and Arterial Stiffness but Improvement in Several Markers of Endothelial Function after Initiation of Antiretroviral Therapy J Infect Dis 199 1186 1194 10.1086/597475 19275490
35. •• Ross AC, Rizk N, O'Riordan MA et al.: Relationship between Inflammatory Markers, Endothelial Activation Markers, and Carotid Intima-Media Thickness in HIV-Infected Patients Receiving Antiretroviral Therapy. Clin Infect Dis 2009; 49:1119-27. Case-control cross-sectional study correlating hsCRP and sVCAM with cIMT in 73 subjects with HIV.
36. S Parra B Coll G Aragones, et al. 2010 Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation HIV Medicine 11 225 231 1:CAS:528:DC%2BC3cXkvVSktbg%3D 10.1111/j.1468-1293.2009. 00766.x 19845792